DDInter1161 DDInter1376
Metamfetamine (methamphetamine) is a psychostimulant and sympathomimetic drug, and a member of the amphetamine group of sympathomimetic amines. Methamphetamine can induce effects such as euphoria, increased alertness and energy, and enhanced self-esteem. It is a scheduled drug in most countries due to its high potential for addiction and abuse. The FDA withdrew its approval for the use of all parenteral drug products containing methamphetamine hydrochloride, a metamfetamine salt.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Metamfetamine {u} (Compound) resembles {v} (Compound) Benzphetamine
Metamfetamine {u} (Compound) resembles {v} (Compound) Phenacemide
Metamfetamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ephedrine
Metamfetamine {u} may lead to a major life threatening interaction when taken with {v} Dexfenfluramine
Metamfetamine {u} (Compound) treats {v} (Disease) obesity
Metamfetamine {u} (Compound) binds {v} (Gene) ADRA2C
Metamfetamine {u} (Compound) palliates {v} (Disease) attention deficit hyperactivity disorder
Metamfetamine {u} (Compound) is included by {v} (Pharmacologic Class) Central Nervous System Stimulation
Metamfetamine {u} (Compound) causes {v} (Side Effect) Tourette's disorder
Metamfetamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Magaldrate
Metamfetamine (Compound) resembles Benzphetamine (Compound)
Metamfetamine (Compound) resembles Phenacemide (Compound)
Metamfetamine may cause a moderate interaction that could exacerbate diseases when taken with Ephedrine
Metamfetamine may lead to a major life threatening interaction when taken with Dexfenfluramine
Metamfetamine (Compound) treats obesity (Disease)
Metamfetamine (Compound) binds ADRA2C (Gene)
Metamfetamine (Compound) palliates attention deficit hyperactivity disorder (Disease)
Metamfetamine (Compound) is included by Central Nervous System Stimulation (Pharmacologic Class)
Metamfetamine (Compound) causes Tourette's disorder (Side Effect)
Metamfetamine may cause a moderate interaction that could exacerbate diseases when taken with Magaldrate